Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2020-12-17 Regulatory Filings
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended October 31, 2020. It is a Form 52-109FV2 Certification of Interim Filings for a venture issuer. The content is primarily an officer certification attesting to the accuracy and fair presentation of the interim filings, without containing actual financial data or the interim report itself. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is short (3016 characters), and it is clearly a certification letter rather than a full interim report.
2020-12-17 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended October 31, 2020. It is a certification letter related to interim filings, not the interim report itself. The document is short (3010 characters) and primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS), not as the interim report (IR).
2020-12-17 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Consolidated Financial Statements For the six months ended October 31, 2020 (Unaudited - Expressed in Canadian Dollars)' and contains detailed financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, cash flows, and notes to the financial statements. The period covered is six months, which is less than a full fiscal year, indicating an interim report. The document is unaudited and prepared by management, consistent with interim or quarterly reporting. There is no indication that this is an annual report or a full year report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2020-12-17 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) and is prepared as of December 17, 2020. It reviews operations, financial position, and outlook for the company, referencing interim consolidated financial statements for the six months ended October 31, 2020. The content includes detailed discussion of financial results, expenses, revenues, share issuances, and corporate activities during the period. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The MD&A is a management report explaining financial results and business trends, which fits the definition of Management Reports (MDA). It is not an Annual Report (10-K), Interim Report (IR) because it is specifically a Management Discussion and Analysis document, nor is it a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is MDA with high confidence.
2020-12-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the outcome of a pre-submission meeting with the FDA regarding the company's Breast CT Imaging System. It discusses the company's confidence in its market approval plan and future business objectives. There are no financial statements, detailed financial data, or regulatory filings such as annual or quarterly reports. The content focuses on regulatory interaction and business update rather than financial results or governance changes. It is not a report itself but an announcement of a regulatory interaction and business update. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and business update that does not fit other specific categories.
2020-12-15 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2020-12-11 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.